Evidence map›Paper›PMID 30080850›Full record

ArticlePLoS neglected tropical diseases2018

Stratified sero-prevalence revealed overall high disease burden of dengue but suboptimal immunity in younger age groups in Pune, India.

Akhilesh C Mishra, Vidya A Arankalle, Swapnil A Gadhave, Pritam H Mahadik, Shubham Shrivastava, Mandar Bhutkar, Varsha M Vaidya

Abstract read
In one paragraph

Article in PLoS neglected tropical diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Standardization of ELISA for anti-chikungunya-IgG antibodies and age-stratified prevalence of anti-chikungunya-IgG antibodies in Pune, India.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Akhilesh C MishraInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.ORCID 0000-0003-1836-1990
Vidya A ArankalleInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.
Swapnil A GadhaveInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.
Pritam H MahadikInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.
Shubham ShrivastavaInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.ORCID 0000-0002-5980-8536
Mandar BhutkarInteractive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.
Varsha M VaidyaDepartment Community Medicine, Medical College, Bharati Vidyapeeth (Deemed to be University), Katraj, Pune, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn India, dengue disease is emerging as the most important vector borne public health problem due to rapid and unplanned urbanization, high human density and week management of the disease. Clinical cases are grossly underreported and not much information is available on prevalence and incidence of the disease. METHODOLOGY: A cross sectional, stratified, facility based, multistage cluster sampling was conducted between May 4 and June 27, 2017 in Pune city. A total of 1,434 participants were enrolled. The serum samples were tested for detection of historical dengue IgG antibodies by ELISA using the commercial Panbio Dengue IgG Indirect ELISA kit. Anti-dengue IgG-capture Panbio ELISA was used for detection of high titered antibodies to detect recent secondary infection. We used this data to estimate key transmission parameters like force of infection and basic reproductive number. A subset of 120 indirect ELISA positive samples was also tested for Plaque Reduction Neutralizing Antibodies for determining serotype-specific prevalence.

findingsOverall, 81% participants were infected with dengue virus (DENV) at least once if not more. The positivity was significantly different in different age groups. All the adults above 70 years were positive for DENV antibodies. Over 69% participants were positive for neutralizing antibodies against all 4 serotypes suggesting intense transmission of all DENV serotypes in Pune. Age-specific seroprevalence was consistent with long-term, endemic circulation of DENV. There was an increasing trend with age, from 21.6% among <36 months to 59.4% in age group 10-12 years. We estimate that 8.68% of the susceptible population gets infected by DENV each year resulting into more than 3,00,000 infections and about 47,000 to 59,000 cases per year. This transmission intensity is similar to that reported from other known hyper-endemic settings in Southeast Asia and the Americas but significantly lower than report from Chennai.

conclusionsOur study suggests that Pune city has high disease burden, all 4 serotypes are circulating, significant spatial heterogeneity in seroprevalence and suboptimal immunity in younger age groups. This would allow informed decisions to be made on management of dengue and introduction of upcoming dengue vaccines in the city.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, NeutralizingAntibodies, ViralChildChild, PreschoolCross-Sectional StudiesDengueDengue VirusEnzyme-Linked Immunosorbent AssayFemaleHumansImmunoglobulin GIndiaAntibodies, NeutralizingAntibodies, ViralImmunoglobulin G

Identifiers

PMID30080850
PMCPMC6095695

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.